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Introduction
Membrane-associated metalloendopeptidases play a major role in 
the post-secretory processing of regulatory peptides. Cell surface 
peptidases cleave peptides in the extracellular fl  uid to generate bi-
ologically active forms or inactivate mature peptides. For exam-
ple, angiotensin-converting enzyme-1 converts angiotensin (AT) I 
to ATII, which activates the ATII type 1A receptor (AT1AR), and 
degrades bradykinin (BK) to limit activation of the BK B2 recep-
tor (B2R) (Yang et al., 1970, 1971). Neprilysin (NEP) degrades 
substance P (SP) to limit activation of the neurokinin-1 receptor 
(NK1R) and terminate neurogenic infl  ammation (Okamoto et al., 
1994; Lu et al., 1997; Sturiale et al., 1999). Less is known about 
the role of intracellular membrane metalloendopeptidases.
Endothelin-converting enzyme 1 (ECE-1) is a metallo-
endopeptidase of plasma and endosomal membranes. Four ECE-1 
isoforms (a–d) arise from a single gene using alternate promoters 
(Schmidt et al., 1994; Shimada et al., 1995; Schweizer et al., 
1997; Valdenaire et al., 1999). Whereas ECE-1 isoforms share a 
common catalytic domain, differences in the N-terminal domains 
specify variable subcellular distribution (Schweizer et al., 1997; 
Azarani et al., 1998; Brooks et al., 2000; Muller et al., 2003; 
Hunter and Turner, 2006). ECE-1b and ECE-1d are mainly pre-
sent in endosomal membranes (Schweizer et al., 1997; Azarani 
et al., 1998; Muller et al., 2003), and ECE-1a and ECE-1c are 
mainly at the plasma membrane, with a minor localization 
in endosomes (Schweizer et al., 1997; Muller et al., 2003). 
Cell surface ECE-1 converts big-endothelin (ET) to the pressor 
peptide ET-1 (Xu et al., 1994), and inactivates BK (Hoang 
and Turner, 1997). The function of ECE-1 in endosomes is not 
fully understood. However, ECE-1 can degrade neuropeptides 
such as SP, BK, ATI, and neurotensin at an acidic endosomal pH 
(Johnson et al., 1999; Fahnoe et al., 2000). Because many peptides 
traffi  c to endosomes with their receptors, we hypothesized that 
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lthough cell surface metalloendopeptidases de-
grade neuropeptides in the extracellular ﬂ  uid to 
terminate signaling, the function of peptidases in 
endosomes is unclear. We report that isoforms of endothelin-
converting enzyme-1 (ECE-1a–d) are present in early 
endosomes, where they degrade neuropeptides and regulate 
post-endocytic sorting of receptors. Calcitonin gene-related 
peptide (CGRP) co-internalizes with calcitonin receptor-
like receptor (CLR), receptor activity-modifying protein 1 
(RAMP1),  β-arrestin2, and ECE-1 to early endosomes, 
where ECE-1 degrades CGRP. CGRP degradation pro-
motes CLR/RAMP1 recycling and β-arrestin2 redistribution 
to the cytosol. ECE-1 inhibition or knockdown traps CLR/
RAMP1 and β-arrestin2 in endosomes and inhibits CLR/
RAMP1 recycling and resensitization, whereas ECE-1 over-
expression has the opposite effect. ECE-1 does not reg-
ulate either the resensitization of receptors for peptides 
that are not ECE-1 substrates (e.g., angiotensin II), or the 
recycling of the bradykinin B2 receptor, which transiently 
interacts with β-arrestins. We propose a mechanism by 
which endosomal ECE-1 degrades neuropeptides in en-
dosomes to disrupt the peptide/receptor/β-arrestin com-
plex, freeing internalized receptors from β-arrestins and 
promoting recycling and resensitization.
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ECE-1 degrades peptides in endosomes to disrupt the peptide/
receptor complex and to control post-endocytic sorting and sig-
naling of receptors.
Little is known about post-endocytic sorting of G protein–
coupled receptors (GPCRs). Endocytosis requires receptor 
phosphorylation by G protein receptor kinases, which increases 
the affi  nity of the receptor for β-arrestins. β-arrestins trans-
locate from the cytosol to the plasma membrane, where they un-
couple receptors from heterotrimeric G proteins to mediate 
desensitization (Lohse et al., 1990), and couple receptors to 
clathrin and AP2 to mediate endocytosis (Ferguson et al., 1996; 
Goodman et al., 1996). One determinant of the rate of recycling 
is the affi  nity of receptors for β-arrestins. “Class A” GPCRs 
(e.g., β2 adrenergic receptor, B2R, μ-opioid receptor, neurokinin 3 
receptor) have few phosphorylation sites, interact transiently 
with β-arrestin2 with low affi  nity, and rapidly recycle (Oakley 
et al., 1999, 2000, 2001; Schmidlin et al., 2003). “Class B” GPCRs 
(e.g., AT1AR, NK1R, neurotensin receptor 1, vasopressin V2 
receptor [V2R]) are highly phosphorylated, interact with both 
β-arrestin1 and 2 with high affi  nity for prolonged periods in endo-
somes, and slowly recycle. Although dissociation from β-arrestins 
is necessary for receptor recycling and resensitization, the critical 
event that initiates this process is unknown.
We recently reported that ECE-1 degrades SP in acidifi  ed 
endosomes to disrupt the SP/NK1R/β-arrestin complex, and ini-
tiate NK1R recycling and resensitization (Roosterman et al., 
2007). However, it is not known whether this is a general mech-
anism that regulates traffi  cking of other GPCRs and associated 
proteins. The factors that specify this role for endosomal ECE-1, 
including peptide susceptibility to ECE-1 degradation, peptide 
traffi  cking to ECE-1–containing endosomes, and receptor affi  n-
ity for β-arrestins, are unknown. To address these questions, we 
examined the role of ECE-1 in post-endocytic sorting of the re-
ceptor for calcitonin gene-related peptide (CGRP), a heterodimer 
of the calcitonin receptor-like receptor (CLR) and receptor 
activity-modifying protein 1 (RAMP1) (McLatchie et al., 1998). 
CGRP induces β-arrestin–dependent endocytosis of CLR/
RAMP1, which remains associated with β-arrestins in endosomes, 
typical of a “class B” GPCR (Hilairet et al., 2001), and then re-
cycles (Cottrell et al., 2007). CGRP is a potent vasodilator and a 
major mediator of neurogenic infl  ammation (Brain and Grant, 
2004). Given its prominent expression in the endothelium (Korth 
et al., 1999), ECE-1 may regulate these vasoactive actions 
of CGRP. However, it is not known whether ECE-1 degrades 
CGRP, and the role of ECE-1 in regulating CLR/RAMP1 is 
completely unexplored. We also examined the role of ECE-1 in 
regulating receptors for two other vasoactive peptides that are 
potential ECE-1 substrates: AT1AR, a prototypical “class B” 
GPCR (Oakley et al., 2000), and B2R, which transiently inter-
acts with β-arrestins and rapidly recycles (Simaan et al., 2005).
Results
ECE-1 is endogenously expressed in HEK, 
SK-N-MC, and A549 cells
Using RT-PCR with isoform-specifi  c primers, we amplifi  ed mRNA 
encoding ECE-1a–d from HEK, SK-N-MC, and A549 cells, 
and confirmed identity by sequencing (Fig. S1 A, available 
at http://www.jcb.org/cgi/content/full/jcb.200704053/DC1). 
We amplifi  ed transcripts of B2R in HEK cells, CLR and RAMP1 
in SK-N-MC cells, and AT1AR in A549 cells (Fig. S1 A). We de-
tected ECE-1 ( 120 kD) in membranes from HEK, SK-N-MC, 
and A549 cells by Western blotting (antibody 473–17-A to all 
ECE-1 isoforms) (Fig. S1 B). Thus, HEK, SK-N-MC and A549 
cells express all ECE-1 isoforms.
ECE-1 isozymes are present 
in early endosomes
We examined the subcellular localization of ECE-1a-d-GFP ex-
pressed in HEK cells. All ECE-1 isoforms colocalized with 
early endosomal antigen 1 (EEA1) to varying extents. ECE-1b and 
ECE-1d prominently colocalized with EEA1 (Fig. 1 A, arrows). 
ECE-1a and ECE-1c were mainly at the plasma membrane 
(Fig. 1 A, arrowheads), but sometimes colocalized with EEA1 
(Fig. 1 A, arrows). To confi  rm the endosomal localization of 
ECE-1a-d, we coexpressed ECE-1a-d-GFP with Rab5aQ79L-
CFP, a constitutively active mutant that causes endosomal fusion, 
facilitating detection of proteins in endosomes (Stenmark et al., 
1994). All isoforms of ECE-1 prominently colocalized with 
Rab5aQ79L in enlarged endosomes (Fig. 1 B, arrows), although 
ECE-1a and ECE-1c were also detected at the plasma membrane 
(Fig. 1 B, arrowheads).
Because overexpression may alter the subcellular dis-
tribution of ECE-1, we localized endogenous ECE-1 (antibody 
52–6497). This antibody recognized ECE-1b and ECE-1d, but not 
ECE-1a or ECE-1c expressed in KNRK cells, and untransfected 
KNRK cells, which do not express ECE-1 mRNA, were un-
stained (unpublished data). In HEK, SK-N-MC, and A549, 
immunoreactive ECE-1b/d colocalized with EEA1 (Fig. 1, C–E; 
arrows). Staining of HEK cells was abolished by preabsorption 
with the ECE-1 fragment used for immunization (Fig. 1 C, right). 
Thus, endogenous ECE-1b/d are present in early endosomes.
CGRP and CLR trafﬁ  c from the plasma 
membrane to early endosomes 
containing ECE-1
To determine whether CGRP traffi  cs to endosomes contain-
ing ECE-1, we incubated HEK-CLR-RAMP1 cells expressing 
ECE-1a-d-GFP with Alexa-CGRP (100 nM). After 1 h at 4°C, 
CGRP was at the plasma membrane, and ECE-1 isoforms were 
in endosomes or at the plasma membrane (Fig. 1 F). After wash-
ing and 30 min incubation at 37°C, CGRP was prominently co-
localized in endosomes with ECE-1b and ECE-1d (Fig. 1 F, 
arrows). Some endosomes containing CGRP also contained 
ECE-1c and were in proximity to intracellular ECE-1a (Fig. 1 F, 
arrows). CGRP was also prominently detected in early endosomes 
with endogenous immunoreactive ECE-1b/d and EEA1 in HEK-
CLR-RAMP1 cells (Fig. 1 G, arrows). In HEK-CLR-RAMP1 
cells expressing ECE-1a-d-GFP, CGRP (100 nM, 30 min, 37°C) 
induced traffi  cking of immunoreactive CLR to endosomes con-
taining ECE-1b and ECE-1d (Fig. S2, arrows; available at http://
www.jcb.org/cgi/content/full/jcb.200704053/DC1). Although 
CLR was detected in endosomes in close proximity to intra-
cellular ECE-1a and ECE-1c, colocalization was less apparent. ENDOSOMAL ECE-1 AND RECEPTOR RECYCLING • PADILLA ET AL. 983
Thus, CGRP and CLR traffi  c to early endosomes containing 
ECE-1 isoforms.
ECE-1 hydrolyzes CGRP, ATI, and BK, 
but not ATII, at endosomal pH
The pH optimum for ECE-1 is broad and substrate dependent 
(Johnson et al., 1999; Fahnoe et al., 2000). Although ECE-1 
  converts big-ET to ET-1 at a neutral pH optimum (pH 6.8–7.0), 
consistent with generating ET-1 at the cell surface, ECE-1 hydro-
lyzes SP and ATI at an acidic pH optimum (pH 5.6–5.8), similar 
to that of endosomes. To determine if ECE-1 degrades CGRP 
at endosomal pH, we incubated CGRP with recombinant hu-
man (rh) ECE-1 at endosomal pH 5.5 (Pelkmans et al., 2004). 
rhECE-1 degraded CGRP in a concentration-dependent manner 
(Fig. 2, A and B). The major products separated by HPLC were 
CGRP[15–26], CGRP[27–37], CGRP[1–24], and CGRP[1–26], 
indicating hydrolysis of Gly
14-Leu
15, Lys
24-Asp
25, and Asn
26-Phe
27 
bonds (Fig. S3, available at http://www.jcb.org/cgi/content/full/
jcb.200704053/DC1). Additional products were also identifi  ed 
when digests were analyzed by mass spectrometry, indicating 
Figure 1.  ECE-1 isozymes are present in early endosomes. (A) Localization of ECE-1a-d-GFP and EEA1 in HEK cells. All ECE-1 isoforms, especially ECE-1b 
and ECE-1d, colocalized with immunoreactive EEA1 (arrows). ECE-1a and ECE-1c were also at the plasma membrane (arrowheads). (B) Localization of 
ECE-1a-d-GFP and Rab5aQ79L-CFP in HEK cells. Rab5aQ79L colocalized in enlarged endosomes with ECE-1a-d (arrows). (C–E) Colocalization of endog-
enous ECE-1 and EEA1 (arrows) in HEK (C), SK-N-MC (D), and A549 (E) cells. (C, right panel) ECE-1 preabsorption control. (F) Trafﬁ  cking of Alexa-CGRP 
in HEK-CLR-RAMP1 cells expressing ECE-1a-d-GFP. After 1 h at 4°C, CGRP was at the plasma membrane (arrowheads), shown in HEK-CLR-RAMP1+
ECE-1a-GFP cells. After washing and incubation for 30 min at 37°C, CGRP prominently colocalized with ECE-1b and ECE-1d, sometimes colocalized with 
ECE-1c, and was in proximity to intracellular ECE-1a (arrows). (G) Trafﬁ  cking of Alexa-CGRP in HEK-CLR-RAMP1 cells. After 30 min at 37°C, CGRP colocalized 
with endogenous immunoreactive ECE-1 and EEA1 (arrows). Bar, 10 μm.JCB • VOLUME 179 • NUMBER 5 • 2007  984
hydrolysis of Arg
11-Leu
12, Leu
15-Leu
16, and Val
28-Pro
29 bonds. 
Because the biological activity of CGRP depends on the 8–37 
sequence (Poyner et al., 1998), this hydrolysis would inactivate 
CGRP. CGRP degradation was minimal at extracellular fl  uid pH 
7.4 (Fig. 2 B). The ECE-1 inhibitor SM-19712 (Umekawa et al., 
2000) (100 μM) abolished rhECE-1 degradation of CGRP at pH 
5.5 (Fig. 2 B, Fig. S3). Because ATI is an ECE-1 substrate (Johnson 
et al., 1999), we also examined hydrolysis of ATII. When ATII 
was incubated with 83 nM rhECE-1 at pH 5.5 or 7.4, there was 
no detectable degradation at up to 480 min (Fig. 2 C), although 
rhECE-1 degraded ATI under the same conditions (Fig. 2 C). BK 
is also degraded by ECE-1, but there are confl  icting reports about 
the pH optimum (Hoang and Turner, 1997; Johnson et al., 1999; 
Fahnoe et al., 2000). rhECE-1 (83 nM) degraded BK at pH 5.5 
and 7.4, and SM-19712 prevented this degradation, but degrada-
tion was faster at pH 5.5 (Fig. 2 D). Thus, ECE-1 degrades some 
(CGRP, ATI, BK) but not all (ATII) vasoactive peptides. The pH 
optimum favors degradation in acidifi  ed endosomes and pre-
vents degradation at the cell surface.
ECE-1 degrades endocytosed CGRP
To examine the contribution of ECE-1 to the degradation of 
endocytosed CGRP, we incubated HEK-CLR-RAMP1 cells with 
125I-His
8-CGRP and fractionated cell lysates and medium by 
HPLC. Internalized 
125I-His
8-CGRP was rapidly degraded to pro-
ducts with HPLC retention times of 3 min (
125I-His) and 15 min 
Figure 2.  ECE-1 degrades neuropeptides at endosomal pH. (A–D) Degradation of peptides by rhECE-1 at pH 5.5 and 7.4 assessed byHPLC. (A) CGRP 
cleavage sites; solid line shows bioactive region. (B–D) Time course of degradation of GCRP (B), ATI and II (C), and BK (D). (E–G) Degradation of 
125I-His
8-
CGRP by HEK-CLR-RAMP1 cells. 
125I-His
8-CGRP was incubated with cells for 5 or 10 min, cells were acid-washed, and incubated for 0, 15, 30, or 60 min. 
The percentage of recovered counts eluting as intact CGRP or metabolites in cell lysates or medium was determined by HPLC; standard errors within symbols. 
(E) Time course of degradation of endocytosed 
125I-His
8-CGRP. (F) Time course of appearance of metabolites in lysates and medium. (G) Effects of SM-19712 
and baﬁ  lomycin A1 on degradation of 
125I-His
8-CGRP at 30 min after internalization. *, P < 0.05 compared with vehicle.ENDOSOMAL ECE-1 AND RECEPTOR RECYCLING • PADILLA ET AL. 985
(unidentifi  ed peptide) (Fig. 2, E and F; Fig. S3). SM-19712 and 
bafi  lomycin A1, an inhibitor of vacuolar-type H
+-ATPase, pre-
vented degradation of 
125I-His
8-CGRP (Fig. 2 G). Thus, ECE-1 
degrades CGRP in endosomes, and endosomal acidifi  cation is 
necessary for degradation.
ECE-1 inhibition and knockdown slows CLR 
and RAMP1 recycling
Acidotropic agents suppress recycling and resensitization of 
many GPCRs, including CLR/RAMP1 and NK1R (Grady et al., 
1995; Garland et al., 1996; Cottrell et al., 2007). We determined 
whether ECE-1, by degrading CGRP in acidifi  ed endosomes, 
promotes dissociation of CGRP from CLR/RAMP1 to accelerate 
recycling. Cell surface receptors were labeled by incubating HEK-
CLR-RAMP1 cells with antibodies to extracellular CLR (HA11) 
and RAMP1 (Myc) epitopes. Cells were exposed to CGRP 
(100 nM, 1 h, 37°C), washed, and recovered in CGRP-free me-
dium. In unstimulated cells, CLR and RAMP1 colo  calized at 
the plasma membrane (Fig. 3, A and B; arrowheads). In vehicle-
treated cells (DMSO), CGRP caused internalization of CLR and 
RAMP1 into the same endosomes after 1 h (Fig. 3 A, arrows). 
CLR and RAMP1 recycled from 2–6 h (Fig. 3 A, arrowheads). 
Figure 3.  ECE-1 inhibition or knockdown suppresses CLR and RAMP1 recycling. Cells were incubated with CGRP, washed (W), and recovered in CGRP-
free medium. (A) In unstimulated vehicle-treated cells, CLR and RAMP1 colocalized at the plasma membrane (arrowheads). After incubation with CGRP for 
1 h, CLR and RAMP1 colocalized in endosomes (arrows). After 2–6 h recovery, CLR and RAMP1 had recycled (arrowheads). (B) SM-19712 caused reten-
tion of CLR and RAMP1 in endosomes and prevented recycling. (C) In cells transfected with control siRNA, endogenous ECE-1 was readily detected, and 
CGRP induced endocytosis (arrows) and recycling (arrowheads) of CLR. In cells transfected with ECE-1 siRNA, endogenous ECE-1 was barely detectable, 
and CLR internalized and was retained in endosomes (arrows). Bar, 10 μm. (D) Quantiﬁ  cation of the effect of SM-19712 and ECE-1 siRNA on CLR recycling 
at 6 h, showing the percentage of total cellular ﬂ  uorescence at the plasma membrane. *, P < 0.05.JCB • VOLUME 179 • NUMBER 5 • 2007  986
SM-19712 did not affect endocytosis of CLR/RAMP1 (Fig. 3 B, 
arrows), but caused their retention in endosomes even at 6 h (Fig. 
3 B, arrows). To confi  rm the role of ECE-1 in CLR recycling, we 
used siRNA to knockdown ECE-1. ECE-1 siRNA suppressed 
levels of ECE-1 detected by Western blotting by 71 ± 7% after 
72 h, whereas control siRNA had a minimal effect (10 ± 6% 
reduction) compared with untransfected cells (Fig. S4, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200704053/DC1). 
Figure 4.  ECE-1 inhibition suppresses post-endocytic trafﬁ  cking of 𝗃-arrestin2 (𝗃ARR2)-GFP and CLR. HEK-CLR-RAMP1+βARR2-GFP cells were incubated 
with CGRP, washed, and recovered in CGRP-free medium. (A) In unstimulated vehicle-treated cells, β-arrestin2 was cytosolic and CLR was at the plasma 
membrane. After 2 min with CGRP, β-arrestin2 was at the plasma membrane (arrowheads), and after 1 h β-arrestin2 and CLR colocalized in endosomes 
(arrows). After 1 h recovery, β-arrestin2 was mostly cytosolic and CLR remained in endosomes, and after 2–4 h β-arrestin2 was cytosolic and CLR was at the 
plasma membrane. (B) SM-19712 caused retention of β-arrestin2 and CLR in endosomes (arrows). Bar, 10 μm. (C) Colocalization coefﬁ  cient of β-arrestin2 
and CLR at 4 h recovery, showing approximately threefold increase in colocalization in cells treated with SM-19712. *, P < 0.05.ENDOSOMAL ECE-1 AND RECEPTOR RECYCLING • PADILLA ET AL. 987
ECE-1 siRNA also down-regulated ECE-1 detected by immuno-
fl  uorescence (Fig. 3 C). In cells transfected with control siRNA, 
CGRP induced CLR endocytosis and recycling (Fig. 3 C). In cells 
transfected with ECE-1 siRNA, CLR was retained in endosomes 
after 6 h. Quantifi  cation of CLR at the plasma membrane after 
6 h revealed that SM-19712 and ECE-1 siRNA inhibited re-
cycling of CLR by >50% (Fig. 3 D). Thus, active ECE-1 is 
necessary for CLR and RAMP1 recycling.
Inhibition of ECE-1 and endosomal 
acidiﬁ  cation prolongs the interaction 
between 𝗃-arrestin2 and CLR
We similarly determined if ECE-1 is necessary for the dissocia-
tion of CLR and β-arrestins in endosomes of HEK-CLR-RAMP1 
cells expressing β-arrestin2-GFP. In unstimulated cells, β-arrestin2 
was cytosolic and CLR was at the plasma membrane (Fig. 4, 
A and B). In vehicle-treated cells, CGRP induced the transloca-
tion of β-arrestin2 to the plasma membrane after 2 min (Fig. 4 A, 
arrowheads) and caused endocytosis of CLR and β-arrestin2 
into the same endosomes after 1 h (Fig. 4 A, arrows). After 1 h 
recovery, β-arrestin2 had returned to the cytosol and CLR was 
in endosomes. After 2–4 h, CLR was at the plasma membrane. 
SM-19712 did not affect CGRP-induced membrane transloca-
tion of β-arrestin2 or internalization of CLR and β-arrestin2, 
but caused their retention in endosomes (Fig. 4 B, arrows). The 
colocalization coeffi  cient of CLR and β-arrestin2 at 4 h was 
approximately threefold higher in cells treated with SM-19712 
compared with controls (Fig. 4 C). Thus, ECE-1 is necessary for 
the dissociation of β-arrestins from the receptor in endosomes, 
and the return of β-arrestins to the cytosol.
To examine the role of endosomal acidifi  cation in the traf-
fi  cking of CLR, RAMP1, and β-arrestin2, we treated cells with 
bafi  lomycin A1. In vehicle-treated cells, CGRP induced traffi  ck-
ing of CLR, RAMP1, and β-arrestin2 into the same endosomes 
after 1 h (Fig. 5 A, arrows). At 1 h recovery, CLR and RAMP1 
remained in endosomes, and β-arrestin2 was cytosolic, and at 4 h 
CLR and RAMP1 were at the plasma membrane (Fig. 5 A). 
Bafi  lomycin A1 did not affect CGRP-induced traffi  cking of CLR, 
RAMP1, and β-arrestin2 to endosomes (Fig. 5 B, arrows), but 
caused retention of CLR, RAMP1, and β-arrestin2 in endosomes 
for up to 4 h recovery (Fig. 5 B, arrows). The colocalization co-
effi  cient of CLR and β-arrestin2 at 4 h was more than twofold 
higher in cells treated with bafi  lomycin A1 compared with con-
trol cells (Fig. 5 C). Thus, endosomal acidifi  cation is necessary 
for the redistribution of β-arrestin2 to the cytosol and for CLR 
and RAMP1 recycling.
Acidiﬁ  cation promotes the dissociation 
of CGRP from CLR/RAMP1
By inducing the dissociation of CGRP from CLR and RAMP1, 
endosomal acidifi  cation may promote recycling and resensitiza-
tion of CLR and RAMP1 and the return of β-arrestin2 to the 
cytosol. Therefore, we examined binding of 
125I-CGRP to mem-
branes from HEK-CLR-RAMP1 in buffers of graded pH (7.5–5.0). 
Although binding was similar from pH 7.5 to pH 6.5, it sharply 
declined at pH <6.5, with a >30% reduction at pH 6.0 and a 
>75% reduction at pH 5.5 (Fig. 5 D). At endosomal pH 5.5, 
 20% of CGRP was bound to CLR/RAMP1. By degrading 
CGRP in endosomes to forms that are unable to rebind CLR/
RAMP1, ECE-1 may promote the further dissociation of CGRP 
from CLR/RAMP1.
Endosomal ECE-1 regulates resensitization 
of CGRP signaling
To determine if ECE-1-induced recycling of CLR/RAMP1 me-
diates resensitization, we examined the effect of ECE-1 inhibition, 
knockdown, or overexpression on resensitization of CGRP-
induced Ca
2+ signaling.
HEK-CLR-RAMP1 cells were preincubated with CGRP 
(100 nM, 1 h, 37°C) or vehicle (control), washed, and recovered 
in CGRP-free medium for 0–6 h. The change in [Ca
2+]i to a 
second CGRP challenge (30 nM) was measured. Preincubation 
with CGRP abolished CGRP-induced Ca
2+ signals at 0 h recov-
ery, indicating complete desensitization (Fig. S5 A, available 
at http://www.jcb.org/cgi/content/full/jcb.200704053/DC1). 
In cells with active ECE-1, responses to CGRP fully resensitized at 
4–6 h recovery (Fig. 6 A). SM-19712 did not affect desensitiza-
tion but strongly inhibited resensitization at all times (Fig. 6 A). 
We obtained similar results in SK-N-MC cells. Preincubation with 
CGRP (100 nM, 1 h, 37°C) completely desensitized responses 
to CGRP challenge (100 nM) (Fig. S5 B). After 4 h recovery, 
responses to CGRP were resensitized by 54 ± 5% (Fig. 6 B). 
SM-19712 did not affect desensitization, but strongly inhibited 
resensitization at 4 h (33% inhibition; Fig. 6 B). We used ECE-1 
siRNA to confi  rm the role of ECE-1 in regulating resensitization 
in HEK-CLR-RAMP1 cells. In cells treated with control siRNA, 
after 1 h exposure to CGRP (100 nM) and 2 h recovery, CGRP 
(30 nM)-induced Ca
2+ signaling was resensitized by 82 ± 5% 
(Fig. 6 C). ECE-1 siRNA strongly inhibited resensitization at 
2 h (>35% inhibition, Fig. 6 C).
Conversely, we determined whether ECE-1 overexpres-
sion accelerated resensitization of CGRP-induced Ca
2+ signaling. 
In HEK cells expressing CLR/RAMP1 alone (control), CGRP-
induced Ca
2+ signaling was resensitized by 33 ± 2% after 2 h 
(Fig. 6 D). Overexpression of ECE-1a-d accelerated resensitiza-
tion of CGRP-induced Ca
2+ signaling (Fig. 6 D). The most pro-
nounced effect was in cells overexpressing ECE-1c, where there 
was 75 ± 5% resensitization at 2 h.
To determine if ECE-1 degrades CGRP at the cell surface 
to attenuate signaling, we examined the effects of ECE-1 in-
hibition on responses to a single challenge with CGRP. HEK-
CLR-RAMP1 or SK-N-MC cells were treated with vehicle or 
SM-19712 and then challenged with CGRP (30 nM for HEK-
CLR-RAMP1, 100 nM for SK-N-MC). SM-19712 did not affect 
magnitude or duration of CGRP-induced increases in [Ca
2+]i in 
HEK-CLR-RAMP1 cells (Fig. 6 F) or SK-N-MC cells (Fig. 6 F). 
ECE-1 siRNA did not affect the response to an initial challenge 
with CGRP (unpublished data). Thus, ECE-1 is a major deter-
minant of CLR/RAMP1 resensitization.
ECE-1 isoforms co-internalize with CGRP
Although ECE-1c was mainly at the cell surface, overexpression 
of ECE-1c had the largest effect on resensitization of CGRP-
induced Ca
2+ signaling. The observation that overexpression of JCB • VOLUME 179 • NUMBER 5 • 2007  988
Rab5aQ79L caused a pronounced localization of ECE-1c in en-
dosomes suggests that this isoform constitutively internalizes, 
becoming trapped in enlarged endosomes. To examine traffi  ck-
ing of ECE-1 from the plasma membrane, we incubated HEK 
cells expressing ECE-1a-d-HSV with FITC-labeled antibody to 
the extracellular HSV epitope. When incubated with HSV anti-
body for 1 h at 4°C, ECE-1a-d-HSV were detected at the plasma 
membrane (Fig. 7 A, arrowheads). At 30 min after washing and 
Figure 5.  Acidiﬁ  cation regulates post-endocytic trafﬁ  cking of CLR, RAMP1, and 𝗃-arrestin2-GFP. (A–C) Role of endosomal acidiﬁ  cation on trafﬁ  cking of CLR, 
RAMP1 and β-arrestin2-GFP. HEK-CLR-RAMP1+βARR2-GFP cells were incubated with CGRP, washed, and recovered in CGRP-free medium. (A) In unstimu-
lated vehicle-treated cells, β-arrestin2 was cytosolic and CLR and RAMP1 were at the plasma membrane. After incubation with CGRP for 1 h, β-arrestin2, 
CLR, and RAMP1 colocalized in endosomes (arrows). After 1 or 4 h recovery, β-arrestin2 was mostly cytosolic and CLR and RAMP1 recycled at 4 h (arrow-
heads). (B) Baﬁ  lomycin A1 caused retention of β-arrestin2, CLR and RAMP1 in endosomes, preventing the return of β-arrestin2 to the cytosol and CLR/
RAMP1 recycling. Bar, 10 μm. (C) Colocalization coefﬁ  cient of β-arrestin2 and CLR at 4 h recovery, showing greater than twofold increase in colocalization 
in cells treated with baﬁ  lomycin A1. *, P < 0.05. (D) 
125I-CGRP binding to membranes from HEK-CLR-RAMP1 at different pH, expressed as the percentage 
binding at pH 7.5 (100%); standard errors within the symbols.ENDOSOMAL ECE-1 AND RECEPTOR RECYCLING • PADILLA ET AL. 989
warming to 37°C, all isoforms were prominently detected in en-
dosomes (Fig. 7 A, arrows). By expressing ECE-1a-d-HSV in 
HEK-CLR-RAMP1 cells, we determined whether ECE-1a-d-HSV 
co-internalize with Alexa-CGRP. After incubation with HSV 
antibody and Alexa-CGRP at 4°C, ECE-1a-d-HSV colocalized 
with CGRP at the plasma membrane (Fig. 7 B, arrowheads). 
After 30 min at 37°C, ECE-1a-d-HSV colocalized with CGRP in 
endosomes (Fig. 7 C, arrows). Thus, ECE-1 isoforms constitu-
tively internalize and traffi  c with CGRP and CLR/RAMP1 to the 
same endosomes.
To determine whether CGRP promoted endocytosis of 
ECE-1, we used fl  ow cytometry to quantify ECE-1c-HSV at the 
cell surface of HEK-CLR-RAMP1 cells. In cells incubated with 
vehicle for 30 min at 37°C, ECE-1c-HSV at the cell surface was 
55.9 ± 5.0% of that at 4°C (100%), consistent with constitutive 
endocytosis (Fig. 7 D). CGRP (100 nM, 30 min, 37°C) did not 
affect this endocytosis. Thus, activation of CLR/RAMP1 with 
CGRP does not promote ECE-1c endocytosis.
We used immunoprecipitation and Western blotting to 
determine whether CLR interacts with ECE-1c. HEK-CLR-
RAMP1 cells expressing ECE-1c-HSV or empty vector were 
incubated with CGRP (100 nM, 0–30 min, 37°C). ECE-1c was 
immunoprecipitated and blots were probed for ECE-1c and CLR. 
Although ECE-1c was successfully immunoprecipitated and detec-
ted by Western blotting, CLR was not detectable in the immuno-
precipitates before or after treatment with CGRP (Fig. 7 E). There 
were no signals in cells expressing vector control. Thus, ECE-1c 
and CLR do not detectably associate.
AT1AR and B2R resensitize and recycle 
independently of ECE-1
To investigate the selectivity with which ECE-1 controls recep-
tor recycling and resensitization, we examined resensitization of 
the class B AT1AR. HEK-AT1AR cells were preincubated with 
ATII (100 nM, 1 h, 37°C) to desensitize AT1AR or vehicle (control), 
washed, recovered for 20 min or 2 h, and challenged with ATII 
(100 nM). In cells with active ECE-1, ATII-induced Ca
2+ sig-
naling was resensitized to 59 ± 3% at 20 min (Fig. 8 A) and 96 ± 3% 
at 2 h (unpublished data). SM-19712 did not affect resensiti-
zation at either time. SM-19712 also did not affect resensitiza-
tion of responses to ATII in A549 cells expressing endogenous 
AT1AR and ECE-1 (Fig. 8 B). Thus, ECE-1 does not regulate re-
sensitization of AT1AR, consistent with its inability to degrade 
ATII at endosomal pH.
We examined the role of ECE-1 and endosomal acidifi  ca-
tion in regulating resensitization of the class A B2R. HEK cells, 
Figure 6.  ECE-1 regulates the resensitization of CLR and RAMP1. (A–D) Resensitization of CGRP-induced Ca2+ signaling. HEK-CLR-RAMP1 (A, C, and D) 
or SK-N-MC (B) cells were incubated with CGRP (100 nM) or vehicle for 1 h, washed, and challenged with CGRP (30 nM HEK, 100 nM SK-N-MC) at 0–6 h 
recovery. The change in [Ca
2+]i to CGRP challenge was determined, and expressed as % response in vehicle-treated cells (100%). SM-19712 inhibited 
resensitization in HEK-CLR-RAMP1 cells at 0–6 h (A) and in SK-N-MC cells at 4 h (B). (C) ECE-1 siRNA inhibited resensitization in HEK-CLR-RAMP1 cells at 
2 h. (D) Overexpression of ECE-1a-d-GFP in HEK-CLR-RAMP1 cells enhanced resensitization after 2 h. (E and F) Effects of ECE-1 inhibition on CGRP-induced 
Ca
2+ signaling. SM-19712 did not affect the magnitude of response to a single challenge with CGRP (30 nM in HEK-CLR-RAMP1 [panel E], 100 nM in 
SK-N-MC [panel F]). *, P < 0.05 compared with SM-19712 vehicle (DMSO) (A and B), control siRNA (C), or ECE-1 vector control (vc) (D).JCB • VOLUME 179 • NUMBER 5 • 2007  990
which naturally express B2R and ECE-1, were preincubated 
with BK (100 nM, 10 min, 37°C) or vehicle (control), washed, 
and challenged with BK (100 nM) after a 0–120-min recovery. 
Preincubation with BK abolished BK-induced Ca
2+ signals at 
0 min recovery, indicating complete desensitization (Fig. S5 C). 
BK-induced Ca
2+ signaling rapidly resensitized to 45 ± 2% at 
10 min and 87 ± 6% at 120 min recovery (Fig. 8 C). SM-19712 
or bafi  lomycin A1 had no effect on desensitization (Fig. S5 C) or 
resensitization (Fig. 8 C). Thus, although ECE-1 rapidly degrades 
BK at endosomal pH, ECE-1 and endosomal acidifi  cation do not 
affect B2R resensitization. Moreover, neither SM-19712, thior-
phan (NEP inhibitor), nor phosphoramidon (NEP and ECE-1 
inhibitor) affected responses to a single BK (100 nM) challenge 
of HEK cells (Fig. 8 D). Thus, cell surface ECE-1 and NEP do 
not regulate BK-induced activation of the B2R in HEK cells.
One explanation of the lack of involvement of ECE-1 in B2R 
resensitization is that B2R recycles without traffi  cking to ECE-1–
containing endosomes. To examine this possibility, we incu-
bated HEK cells expressing ECE-1a-d-HSV with Alexa-kallidin 
(100 nM, BK with N-terminal Lys labeled with Alexa), an ago-
nist of the B2R, and localized HSV-FITC and Alexa-kallidin. 
After 1 h at 4°C, kallidin and ECE-1a-d-HSV colocalized to the 
plasma membrane (unpublished data). After 10 min at 37°C, 
kallidin prominently colocalized with ECE-1a-d-HSV in endo-
somes (Fig. 9 A for ECE-1b). Kallidin also internalized to localize 
with endogenous immunoreactive ECE-1 in HEK cells (unpub-
lished data). Thus, kallidin and presumably BK and B2R traffi  c 
to endosomes containing ECE-1a-d.
Alternatively, because B2R interacts only transiently with 
β-arrestins (Simaan et al., 2005), B2R may rapidly dissociate 
from β-arrestins to recycle by a mechanism that does not require 
ECE-1 degradation of BK. To assess this possibility, HEK-B2R 
cells expressing β-arrestin2-GFP were incubated with antibody 
to the extracellular B2R HA11 epitope, and then stimulated 
with BK (100 nM, 10 min). After 10 min, B2R and β-arrestin2 
colocalized in endosomes, and after 60 min recovery B2R had 
recycled and β-arrestin2 was cytosolic (Fig. 9 B). SM-19712 
did not affect this traffi  cking (Fig. 9 C). Substitution of the 
Figure 7.  ECE-1 and CGRP co-internalize into the same endosomes. (A–C) ECE-1 trafﬁ  cking. (A) HEK cells expressing ECE-1a-d-HSV were incubated with 
FITC-HSV antibody for 1 h at 4°C, washed, and incubated for 30 min at 37°C. After warming, ECE-1a-d trafﬁ  cked from the plasma membrane (arrow-
heads) to endosomes (arrows). (B and C) Trafﬁ  cking of ECE-1 and Alexa-CGRP. HEK-CLR-RAMP1 cells expressing ECE-1a-d-HSV were incubated with Alexa-
CGRP, and ECE-1 was localized as in A. (B) After 1 h at 4°C, ECE-1a-d-HSV and CGRP colocalized at the plasma membrane (arrowheads). (D) After 30 min 
at 37°C, ECE-1a-d-HSV and CGRP colocalized in endosomes (arrows). Bar, 10 μm. (D) Quantiﬁ  cation of cell surface ECE-1c-HSV by ﬂ  ow cytometry. HEK-
CLR-RAMP1 cells expressing ECE-1c-HSV were incubated with HSV antibody, and incubated with vehicle or CGRP (100 nM) for 30 min. Surface ECE-1c-HSV 
was quantiﬁ  ed by ﬂ  ow cytometry. In vehicle-treated cells, warming resulted in loss of surface ECE-1c, which was not affected by CGRP. *, P < 0.05 to 4°C. 
(E) Immuno  precipitation of ECE-1c and CLR. HEK-CLR-RAMP1 cells expressing ECE-1c or vector control were incubated with CGRP. ECE-1c was immunoprecipitated 
and blots probed for ECE-1c and CLR. ECE-1c but not CLR was detected.ENDOSOMAL ECE-1 AND RECEPTOR RECYCLING • PADILLA ET AL. 991
C terminus of the B2R with that of the class B V2R generates 
a functional receptor (B2R-V2RCT) that shows sustained inter-
actions with β-arrestins (Simaan et al., 2005). BK induced sus-
tained colocalization of B2R-V2RCT and β-arrestin2 in endosomes, 
and B2R-V2RCT recycled more slowly (2 h) than B2R (1 h) 
(Fig. 9 D). SM-19712 inhibited recycling of B2R-V2RCT, causing 
it retention in endosomes with β-arrestin2 (Fig. 9 E). Quanti-
tative analysis confi  rmed that SM-19712 inhibited recycling of 
B2R-V2RCT (>50% reduction) but not B2R (<10% reduction) 
(Fig. 9 F), and caused a twofold increase in the colocalization 
coeffi  cient of B2R-V2RCT with β-arrestin2 (Fig. 9 G). Thus, 
ECE-1 does not control B2R recycling because this receptor inter-
acts transiently with β-arrestins.
Discussion
We have defi  ned a novel role for endosomal ECE-1 in the post-
endocytic sorting of GPCRs and β-arrestins. Our results show 
that CGRP, CLR, RAMP1, β-arrestins, and ECE-1 traffi  c to early 
endosomes (Fig. 10, steps 1–4). ECE-1 degrades CGRP in acid-
ifi  ed endosomes to fragments that are unable to rebind CLR/
RAMP1. This degradation promotes the dissociation of CGRP 
and β-arrestins from CLR/RAMP1, inducing redistribution of 
β-arrestins to the cytosol and recycling and resensitization of 
CLR/RAMP1. This mechanism is specifi  c, because ECE-1 does 
not degrade ATII and thus does not regulate recycling or re-
sensitization of the AT1AR. Moreover, ECE-1 has little effect on 
resensitization of the rapidly recycling B2R that interacts only 
transiently with β-arrestins.
ECE-1 shows isoform-speciﬁ  c localization 
in early endosomes containing CGRP, CLR, 
RAMP1, and 𝗃-arrestins
ECE-1b and ECE-1d were prominently detected in EEA1-positive 
endosomes. Although ECE-1a and ECE-1c were mainly at the 
plasma membrane, they also colocalized with EEA1. All ECE-1 
isoforms, including ECE-1a and ECE-1c, were prominently de-
tected in enlarged endosomes expressing the constitutively active 
Figure 8.  ECE-1 does not regulate ATII or BK Ca
2+ signaling. (A and B) Resensitization of ATII-induced Ca
2+ signaling in HEK-AT1AR cells (A) and A549 
cells (B). Cells were incubated with ATII (100 nM for HEK, 1 μM for A549) or vehicle (veh, control) for 1 h at 37°C, washed and recovered for 20 min 
(HEK) or 1 h (A549). The change in [Ca
2+]i to a second ATII challenge (100 nM for HEK, 1 μM for A549) was determined and expressed as % response 
in the vehicle-treated cells (100%). SM19712 did not affect resensitization. (C) Resensitization of BK-induced Ca
2+ signaling in HEK cells. Cells were incu-
bated with BK (100 nM) or vehicle (veh, control) for 10 min at 37°C, washed and recovered for 0–120 min. Resensitization was identical in cells treated 
with vehicle (DMSO), SM-19712, or baﬁ  lomycin A1. (D) Effects of peptidase inhibitors on BK-induced Ca
2+ signaling in HEK cells. SM-19712, thiorphan, 
and phosphoramidon did not affect responses to a single BK challenge (100 nM).JCB • VOLUME 179 • NUMBER 5 • 2007  992
Figure 9.  ECE-1 does not regulate recycling of the B2R. (A) Localization of Alexa-kallidin and ECE-1b-HSV in HEK cells expressing ECE-1b-HSV. Cells were 
incubated with Alexa-kallidin and FITC-HSV antibody for 1 h at 4°C, washed, and incubated at 37°C for 10 min. Kallidin colocalized with ECE-1b-HSV (arrows). 
(B–E) Effects of ECE-1 inhibition on BK-induced translocation of β-arrestin2-GFP in HEK cells. HEK-B2R cells (B and C) or HEK-B2R-V2RCT cells (D and E) were 
incubated with BK (100 nM) for 0–10 min at 37°C, washed and recovered in BK-free medium for 1–2 h. (B and D) In unstimulated vehicle-treated cells, 
β-arrestin2 was cytosolic (arrows) and B2R and B2R-V2RCT were at the plasma membrane (arrowheads). After 10 min with BK, β-arrestin2 colocalized in 
endosomes with B2R and B2R-V2RCT (arrows). After 1 h (B2R) or 2 h (B2R-V2RCT) recovery, β-arrestin2 was cytosolic and B2R and B2R-V2RCT were at the plasma 
membrane. (C and E) SM-19712 did not affect trafﬁ  cking of B2R or β-arrestin2 (C), but caused retention of β-arrestin2 and B2R-V2RCT in endosomes (E) (arrows). 
Bar, 10 μm. (F) Quantiﬁ  cation of the effect of SM-19712 on recycling of B2R at 1 h recovery and B2R-V2RCT at 2 h recovery. SM-19712 caused an  50% 
reduction in B2R-V2RCT recycling. (G) Colocalization coefﬁ  cient of β-arrestin2 and B2R at 1 h recovery and B2R-V2RCT at 2 h recovery. SM-19712 did not 
affect colocalization with B2R but caused an approximately twofold increase in colocalization with B2R-V2RCT. *, P < 0.05.ENDOSOMAL ECE-1 AND RECEPTOR RECYCLING • PADILLA ET AL. 993
Rab5aQ79L, which stimulates homotypic early endosome fusion 
(Stenmark et al., 1994). These results are consistent with reports 
of the presence of ECE-1b in early, recycling, and late endo-
somes, ECE-1d in recycling endosomes, and ECE-1a and ECE-1c 
at the plasma membrane (Schweizer et al., 1997; Azarani et al., 
1998; Muller et al., 2003).
CGRP, CLR, and RAMP traffi  cked to endosomes contain-
ing ECE-1. Because CLR/RAMP1 and β-arrestin2 prominently 
colocalized in endosomes, β-arrestin2 also colocalizes with 
ECE-1 in endosomes. CGRP and CLR most prominently co-
localized with ECE-1b and ECE-1d, and there was limited co-
localization with ECE-1a and ECE-1c in endosomes. By labeling 
ECE-1 at the cell surface with antibody to an extracellular epi-
tope, we observed constitutive endocytosis of all ECE-1 iso-
forms. Although we cannot exclude the possibility that antibody 
binding caused ECE-1 endocytosis, the prominent localization 
of ECE-1a and ECE-1c in Rab5aQ79QL-containing endosomes 
supports the suggestion of dynamic regulation of these iso-
zymes. Indeed, ECE-1c, and to a lesser extent ECE-1b and 
ECE-1d, constitutively internalize by a dynamin-dependent 
mechanism and recycle (Muller et al., 2003). Notably, all ECE-1 
isoforms co-internalized with Alexa-CGRP. Although flow 
cytometry indicated that CGRP did not affect endocytosis of 
ECE-1c, the possibility that CGRP induces traffi  cking of ECE-1 
from the plasma membrane to endosomes requires further eval-
uation because the subcellular distribution of ECE-1 is regu-
lated by second messenger kinases (Jafri and Ergul, 2006). 
Thus, receptor-activated second messenger kinases may stimulate 
the redistribution of ECE-1 isoforms to endosomes, promoting 
neuropeptide degradation.
ECE-1 degrades CGRP in acidiﬁ  ed 
early endosomes
ECE-1 hydrolyzed six bonds within the biologically active 
C-region of CGRP (8–37), which would inactivate the peptide. 
ECE-1 degraded CGRP at pH 5.5 but not at pH 7.4, in accord 
with the narrow acidic pH optimum reported for ECE-1 degra-
dation of other neuropeptides (Fahnoe et al., 2000). The lack 
of degradation at pH 7.4 suggests that ECE-1 present at the 
plasma membrane is unlikely to degrade CGRP in the extra-
cellular fluid to regulate activation of CLR/RAMP1. Indeed, 
ECE-1 inhibition/knockdown did not affect CGRP-induced 
Ca
2+ signaling in HEK or SK-N-MC cells, which expressed 
ECE-1a and ECE-1c that are known to be at the cell surface. 
The inability of ECE-1 to degrade CGRP and SP in the extra-
cellular fl  uid contrasts with NEP, which degrades SP at the cell 
surface to limit activation of the NK1R (Okamoto et al., 1994) 
(Fig. 10, step 5).
The observation that SM-19712 prevented degradation of 
internalized CGRP in HEK-CLR-RAMP1 cells indicates that 
ECE-1 degrades CGRP in endosomes. The isoform of ECE-1 
that is mainly responsible for the degradation of endocytosed 
CGRP remains to be identifi  ed because all isoforms prominently 
colocalized with Alexa-CGRP. The vacuolar H
+-ATPase inhibitor 
Figure 10.  Metalloendopeptidases regulation of peptide signaling. (1) CGRP binding to CLR and RAMP1 induces G protein receptor kinase (GRK) phos-
phorylation (P) of CLR. β-arrestins translocate to the plasma membrane to interact with phosphorylated CLR. (2) The CGRP/CLR/RAMP1/β-arrestin complex 
undergoes clathrin-, AP2- and dynamin-dependent endocytosis; ECE-1 co-internalizes with the complex. (3) Endosomal acidiﬁ  cation promotes CGRP disso-
ciation from CLR/RAMP1. ECE-1 degrades CGRP in acidic endosomes, preventing CGRP rebinding and promoting dissociation of CGRP and β-arrestin 
from CLR/RAMP1, which allows dephosphorylation of CLR. (4) CLR and RAMP1, freed from CGRP and β-arrestins, recycle and resensitize. (5) NEP 
degrades SP in extracellular ﬂ  uid to limit NK1R activation.JCB • VOLUME 179 • NUMBER 5 • 2007  994
bafilomycin A1 also prevented degradation of endocytosed 
CGRP, indicating a requirement for endosomal acidifi  cation. 
Endosomal acidifi  cation may promote CGRP degradation by 
enhancing ECE-1 activity or by causing CGRP dissociation from 
CLR/RAMP1. ECE-1 probably degrades receptor-dissociated 
CGRP, but it remains to be determined whether ECE-1 degrades 
receptor-associated peptide. Although we did not detect inter-
action of ECE-1c with CLR/RAMP1, another metalloendopepti-
dase, endopeptidase 3.4.24.15, interacts with the C-tails of the 
AT1AR and B2R (Shivakumar et al., 2005). Although principally 
cytosolic, endopeptidase 24.15 has been detected in endosomes 
and degrades BK (Norman et al., 2003). Cathepsin B degrades 
EGF and insulin-like growth factor-I in endosomes (Authier 
et al., 1999, 2005). Thus, several proteases may degrade pep-
tides in endosomes.
Endosomal ECE-1 promotes dissociation of 
CLR/RAMP1 and 𝗃-arrestins in endosomes, 
and induces recycling and resensitization of 
CLR/RAMP1
Several observations suggest that ECE-1 promotes dissociation 
of GPCRs from β-arrestins in endosomes, thereby allowing 
  receptors to recycle. First, ECE-1 inhibition/knockdown pre-
vented CLR/RAMP1 recycling from endosomes. Second, ECE-1 
inhibition prevented the translocation of β-arrestin from endo-
somes to the cytosol. Third, inhibition of vacuolar H
+-ATPase 
prevented CLR/RAMP1 recycling and the return of β-arrestin 
to the cytosol. Thus, although we did not directly examine the 
interactions between CLR/RAMP and β-arrestins, our data sug-
gest that ECE-1, by degrading CGRP in acidifi  ed endosomes, 
promotes dissociation of β-arrestins from CLR/RAMP1, acceler-
ating the return of β-arrestins to the cytosol and of CLR/RAMP1 
to the cell surface. ECE-1–induced dissociation of β-arrestins 
from CLR/RAMP1 may promote the dephosphorylation of CLR 
by endosomal phosphatases, permitting recycled receptors to 
resensitize (Fig. 10, step 3).
Our results suggest that ECE-1 accelerates resensitization 
of CGRP signaling. In HEK-CLR-RAMP1 and SK-N-MC cells, 
ECE-1 inhibition and knockdown markedly delayed resensiti-
zation of CGRP signaling. Thus, the mechanism is not unique to 
cells overexpressing ECE-1, CLR, and RAMP1, but also occurs 
in cells that endogenously express these proteins, and inhibition 
of existing ECE-1 and suppression of ECE-1 synthesis have 
similar effects. Conversely, overexpression of all ECE-1 iso-
forms in HEK-CLR-RAMP1 cells markedly amplifi  ed resensi-
tization of CGRP signaling. Although Alexa-CGRP colocalized 
most prominently with ECE-1b and ECE-1d in endosomes, 
overexpression of ECE-1c had the greatest effect on resensiti-
zation. A likely explanation of this discrepancy is that CGRP 
prominently co-internalizes with ECE-1c, which constitutively 
internalizes and presumably recycles.
β-arrestins recruit components of the MAPK pathway, 
including src and raf-1, to endosomes, allowing endocytosed 
receptors to continue to signal (DeFea et al., 2000a,b; Tohgo 
et al., 2003). ECE-1, by controlling the subcellular distribution 
of β-arrestins, may thereby affect mitogenic signaling of recep-
tors, a possibility that requires further investigation. In support 
of this possibility, inhibitors of cathepsin B, which degrades 
insulin-like growth factor-I in endosomes, markedly infl  uence 
insulin-like growth factor-I signaling (Navab et al., 2001).
Speciﬁ  city of regulation of post-endocytic 
trafﬁ  cking and signaling of GPCRs by 
endosomal ECE-1
ECE-1 is expressed by endothelial, epithelial, smooth muscle, 
and neuronal cells, which are regulated by neuropeptides that 
are potential ECE-1 substrates (Barnes and Turner, 1997, 1999; 
Korth et al., 1999). Endosomal ECE-1 may regulate receptors in 
these cells provided the peptide and its receptor traffi  c to ECE-1–
containing endosomes, and the peptide is an ECE-1 substrate 
at endosomal pH. Our fi  nding that ECE-1 regulates recycling 
and resensitization of CLR/RAMP1 supports the report that 
ECE-1 also degrades tachykinins in endosomes to control re-
cycling and resensitization of the NK1R (Roosterman et al., 
2007). ECE-1 may also control post-endocytic traffi  cking of the 
neurotensin 1 receptor because ECE-1 degrades neurotensin at 
acidic pH (Johnson et al., 1999). CLR/RAMP1, NK1R, and neu-
rotensin receptor 1 are class B GPCRs that colocalize for pro-
longed periods with β-arrestins in endosomes containing ECE-1 
(Oakley et al., 1999, 2000, 2001; Hilairet et al., 2001; Schmidlin 
et al., 2003). AT1AR is also a class B GPCR that slowly recycles 
after activation by ATII. However, ECE-1 did not degrade ATII 
and ECE-1 inhibition did not affect resensitization of ATII-
induced Ca
2+ signaling. Thus, ECE-1 does not regulate all class B 
GPCRs, and further studies are required to determine whether this 
is a general mechanism.
Although ECE-1 rapidly degraded BK at pH 5.5 and the 
B2R agonist kallidin traffi  cked to ECE-1–containing endo-
somes, SM-19712 did not affect B2R recycling or resensitiza-
tion. An explanation for this discrepancy is that B2R is a class A 
GPCR that interacts with low affi  nity with β-arrestins and rap-
idly recycles without a requirement for endosomal acidifi  cation 
or BK degradation. Indeed, bafi  lomycin A1 did not affect resen-
sitization of the B2R. Moreover, SM-19712 strongly inhibited 
recycling of B2R-V2RCT, which shows sustained interactions 
with β-arrestins (Simaan et al., 2005). Thus, the lack of effect of 
an ECE-1 inhibitor on B2R recycling and resensitization signal-
ing may be due to its low affi  nity interactions with β-arrestins. 
Whether ECE-1 regulates traffi  cking and signaling of class A 
GPCRs is unknown.
In summary, we have identifi  ed a new role for endosomal 
ECE-1. ECE-1 co-internalizes with and degrades neuropeptides 
in acidifi  ed endosomes. By degrading peptides to fragments 
that are unable to rebind receptors, ECE-1 destabilizes the peptide/
receptor/β-arrestin complex, and thereby initiates receptor re-
cycling and resensitization. The mechanism requires that pep-
tides are substrates for ECE-1 in acidifi  ed endosomes, and that 
receptors show sustained interactions with β-arrestins which 
are disrupted by endosomal acidifi  cation and peptide degrada-
tion. The observation that ECE-1 inhibitors prevent resensitiza-
tion of responses to CGRP and SP, mediators of infl  ammation 
and pain, suggests that inhibitors of endosomal ECE-1, by at-
tenuating receptor resensitization, may provide a novel therapy 
for peptide-mediated diseases.ENDOSOMAL ECE-1 AND RECEPTOR RECYCLING • PADILLA ET AL. 995
Materials and methods
Antibodies
Source of antibodies were: rabbit antibody to the catalytic domain common 
to all isoforms of human ECE-1 (Korth et al., 1997); goat anti–human ECE-1 
(R&D Systems); rabbit antibody to the N terminus of human ECE-1 (Invitrogen); 
rabbit antibodies to rat CLR and rat RAMP1 (Cottrell et al., 2005); rat high 
afﬁ  nity anti-HA11 (Roche); rabbit anti-Myc (Sigma-Aldrich); goat anti-HSV 
and anti-HSV-FITC (AbCam); goat anti-Myc (Santa Cruz Biotechnology, Inc.); 
mouse anti-early endosomal antigen 1 (EEA1) (BD Transduction Laboratories); 
mouse anti-Na
+K
+-ATPase and mouse anti-HSV (Novus Biologicals); goat 
or donkey anti–mouse, –rat, –rabbit, or –goat IgG coupled to FITC, rhoda-
mine red-X, or Cy5 (Jackson ImmunoResearch Laboratories); goat and don-
key anti–rabbit IgG coupled to AlexaFluor 680 (Invitrogen); and donkey 
anti–mouse IRDye 800 (Rockland Immunochemicals, Inc.).
Reagents
Rat αCGRP, ATI, ATII, BK and kallidin were from Bachem. CGRP and kalli-
din were ﬂ  uorescently labeled with an AlexaFluor 594 labeling kit (Invitro-
gen) (Cottrell et al., 2005). 
125I-His
8 human CGRP was from GE Healthcare. 
rhECE-1 was from R&D Systems. The ECE-1 inhibitor SM-19712 (4-chloro-N-
[(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-yl)amino]carbonyl] benzene-
sulfonamide, monosodium salt) (Umekawa et al., 2000) was from Sigma-Aldrich. 
Other reagents were from Sigma-Aldrich or have been described (Cottrell 
et al., 2007; Roosterman et al., 2007).
cDNAs
cDNAs encoding ECE-1a-d with intracellular N-terminal GFP have been 
described (Roosterman et al., 2007). Constructs of ECE-1a-d with extra-
cellular C-terminal HSV epitope were generated by PCR (primer sequences 
available on request). Constructs of rat CLR and RAMP1 with extracellular 
N-terminal HA11 and Myc epitopes, respectively, have been described 
(Cottrell et al., 2007). To create a vector expressing CLR, RAMP1, and ECE-1  a-
d-GFP, the CLR-RAMP1 vector was digested with BsmI and each ECE-1 
isoform was subcloned into this site with its own CMV promoter and bovine 
growth hormone polyA tail. Human AT1AR was cloned from A549 cells by 
RT-PCR and subcloned into pcDNA5/FRT. Human B2R and B2R-V2RCT with 
N-terminal HA11 epitopes were from S.A. Laporte (McGill University, Mon-
treal, Canada). Rab5aQ79L-GFP was from M. von Zastrow (University of 
California, San Francisco, San Francisco, CA), and a CFP tag was added 
by subcloning. Human β-arrestin2 was cloned from HEK cells using RT-PCR, 
and subcloned into pEGFP-N1. Constructs were sequenced.
Generation and maintenance of cell lines
Sources and maintenance of human embryonic kidney (HEK293) cells, 
sarcoma virus-transformed rat kidney epithelial cells (KNRK), human neuro-
blastoma cells SK-N-MC, and human lung adenocarcinoma cells A549 
have been described (Schmidlin et al., 2003; Cottrell et al., 2007; Roosterman 
et al., 2007). HEKFLP cells stably expressing CLR and RAMP1 have been 
described (Cottrell et al., 2007). In some experiments, cells were transiently 
transfected with CLR/RAMP1, CLR/RAMP1/ECE-1a-d-GFP, ECE-1a-d-GFP, 
ECE-1a-d-HSV, Rab5aQ79L-CFP, or β-arrestin2-GFP using Lipofectamine 
2000 (Invitrogen). Cells were plated 24–48 h before use.
RT-PCR
Total RNA from HEK, SK-N-MC, and A549 cells was analyzed by RT-PCR 
using primers speciﬁ  c for ECE-1 isoforms, and sequenced (Roosterman 
et al., 2007).
SDS-PAGE and Western blotting
Membranes proteins from HEK, SK-N-MC, and A549 cells (15 μg) or 
rhECE-1 (10 ng) were separated by SDS-PAGE, transferred to PVDF mem-
branes, and analyzed by Western blotting using antibodies to ECE-1 
(1:2,000 or 1:1,000) or Na
+K
+-ATPase (1:5,000) (overnight, 4°C) (Cottrell 
et al., 2007; Roosterman et al., 2007). Membranes were incubated with 
secondary antibody conjugated to AlexaFluor 680 (1:20,000, 1 h, room 
temperature), and blots were analyzed with the Odyssey Infrared Imaging 
System (Li-COR Biosciences).
Immunoprecipitation
Proteins were cross-linked using dithiobis(succinimidyl)propionate (Thermo 
Fisher Scientiﬁ   c), lysed with 1 ml RIPA buffer and centrifuged (10 min, 
15,000 g, 4°C). ECE-1c was immunoprecipitated using goat anti-HSV 
(2 μg/ml, 1 h, 4°C). Protein A/G PLUS beads (Santa Cruz Biotechnology, 
Inc.) were added (30 μl, 1 h, 4°C). Immunoprecipitates were analyzed by 
Western blotting using mouse anti-HSV (1:5,000) and CLR (RK11; 1:5,000) 
(overnight, 4°C) (Cottrell et al., 2007).
Subcellular localization of ECE-1, CLR, RAMP1, B2R, B2R-V2RCT, 
Rab5aQ79L, 𝗃-arrestin2, Alexa-CGRP, and Alexa-kallidin
Cells were ﬁ  xed in 4% paraformaldehyde, 100 mM PBS, pH 7.4 (20 min 
at 4°C), and washed for 15 min with PBS, 0.1% saponin, and 1% normal 
goat serum or 2% normal donkey serum. Cells were incubated with pri-
mary antibodies to CLR (1:4,000–8,000), RAMP1 (1:2,000 or goat anti-
Myc, 1:100), ECE-1 (1:500), or EEA1 (1:250) (overnight, 4°C). Cells were 
washed and incubated with ﬂ  uorescent secondary antibodies (1:200–500, 
2 h, room temperature; overnight, 4°C). As a control for speciﬁ  city, the 
ECE-1 antibody was incubated with antigen used for immunization 
(25 μg/ml, 72 h). In some experiments, ECE-1 isoforms, Rab5aQ79L, and 
β-arrestin2 were detected using GFP or CFP. To examine trafﬁ  cking of ﬂ  uor-
escent peptides, cells were incubated with Alexa-CGRP or Alexa-kallidin 
(100 nM) for 1 h at 4°C, washed, incubated at 37°C for speciﬁ  ed times, 
and ﬁ  xed. To examine receptor recycling, CLR, RAMP1, B2R, or B2R-V2RCT 
were labeled at the cell surface by incubating cells with rat anti-HA11 (to 
detect CLR, B2R, or B2R-V2RCT; 1:100) and rabbit or goat anti-Myc (to de-
tect RAMP1; 1:100) for 30 min at 37°C (Cottrell et al., 2007). Cells were 
washed, incubated with CGRP (100 nM, 1 h) or BK (100 nM, 10 min), 
washed, and recovered in agonist-free medium for 0–6 h. To examine ECE-1 
endocytosis, HEK cells expressing ECE-1a  -d-HSV were incubated with goat 
anti-HSV-FITC (1:1,000, 1 h, 4°C) with or without ﬂ  uorescent  peptides. 
Cells were washed and incubated at 37°C for 0–30 min
Confocal microscopy
Cells were observed by using a LSM 510 Meta confocal microscope (Carl 
Zeiss, Inc.) with Plan Apo 100× (NA 1.4) or 63× (NA 1.4) objectives 
(Carl Zeiss, Inc.) (Cottrell et al., 2007; Roosterman et al., 2007). Images 
were collected at a zoom of 1–3 and an iris of <3 μm, and 5–10 optical 
sections were taken at intervals of 0.5 μm. Slides were mounted on Vecta-
shield mounting medium with DAPI (Vector Laboratories) and observed at 
room temperature.
Image analysis
The proportion of the total cellular ﬂ  uorescence at the plasma membrane 
and the colocalization coefﬁ  cient of proteins in endosomes (0, no co-
localization; 1, complete colocalization) were determined using LSM 510 
software (Carl Zeiss, Inc.) (Hasdemir et al., 2007). More than 20 cells 
were analyzed per experiment.
Peptide degradation by ECE-1
Peptides (250 μM) were incubated with rhECE-1 (83 or 415 nM) at 37°C 
in 50 mM MES-KOH, pH 5.5, or 50 mM Tris-HCl, pH 7.4, for 0–720 min 
(Roosterman et al., 2007). The ECE-1 inhibitor SM-19712 (100 μM) was 
preincubated with ECE-1 on ice for 30 min at pH 5.5 or 7.4 before addi-
tion of substrate. Products were separated by reversed-phase HPLC and 
identiﬁ  ed using an ABI 4700 MALDI TOF/TOF mass spectrometer. Mass 
spectrometry data were provided by the UCSF Mass Spectrometry Facility 
(A.L. Burlingame, Director) supported by the Biomedical Research Technology 
Program of the National Center for Research Resources, National Institutes 
of Health (NCRR BRTP 01614).
Endocytosis and degradation of internalized 
125I-CGRP
HEK-CLR-RAMP1 cells (3 × 10
5 cells per 35-mm dish) were incubated in 
HBSS, pH 7.4, 0.1% BSA with CGRP (10 nM unlabeled CGRP, 300,000 cpm 
125I-His
8-CGRP) for 5 or 10 min at 37°C (Roosterman et al., 2007). Cells 
were washed with acidiﬁ  ed HBSS (pH 4.75, acetic acid), 0.1% BSA to 
remove surface-bound label, and incubated in HBSS, pH 7.4, 0.1% BSA 
for 0, 15, 30, or 60 min at 37°C. The medium was collected and acidiﬁ  ed 
with 10% TFA in water. Cells were lysed with 0.1% TFA in water. Samples 
were fractionated by HPLC (Roosterman et al., 2007).
pH dependency of 
125I-CGRP binding to CLR/RAMP1
Membranes from HEK-CLR-RAMP1 cells (20 μl,  200 μg protein) were in-
cubated (90 min, 4°C) with 100,000 cpm 
125I-CGRP in buffers of graded 
acidity: pH 5.0, acetic acid; pH 5.5 and 6.0 MES; pH 6.5 and 7.0 Pipes; 
pH 7.5 Tris (all with 150 mM NaCl, 0.1% BSA, protease inhibitor cocktail, 
20 mM buffer, 300 μl total volume) (Roosterman et al., 2007). Membranes 
were isolated by ﬁ  ltration, washed with corresponding buffer (4°C), and 
the membrane-bound radioactivity was counted. Non-speciﬁ  c binding was 
determined in the presence of 0.1 mM unlabeled CGRP and was sub-
tracted to give speciﬁ  c binding. Results are expressed as the percent bind-
ing at pH 7.5 (100%)JCB • VOLUME 179 • NUMBER 5 • 2007  996
Measurement of [Ca
2+]i
[Ca
2+]i was measured in cells on glass coverslips or in suspension at 37°C 
using Fura-2AM as described (Cottrell et al., 2007; Roosterman et al., 2007). 
To examine responses to a single stimulus, cells were challenged with 
CGRP or BK (30 or 100 nM). To assess desensitization and resensitization, 
cells were incubated with CGRP, ATII, or BK (100–1,000 nM, 1 h, 37°C) 
or vehicle (control), washed, and recovered in agonist-free medium for 20 min 
to 6 h at 37°C. Cells were challenged with CGRP, ATII, or BK (30–1,000 nM), 
and [Ca
2+]i was measured.
Drug treatments
SM-19712 (10 μM), phosphoramidon (1 μM), thiorphan (1 μM), baﬁ  lo-
mycin A1 (0.15 or 1 μM), or vehicle (DMSO, control) was preincubated with 
cells for 20–60 min, and included in buffers throughout the experiment.
siRNA
siRNA reagents were from Dharmacon. ON-TARGET plus SMART pool 
(-005857-00) consisted of four distinct siRNA duplexes targeted to knock-
down of human ECE-1 mRNA. siCONTROL Non-Targeting siRNA pool 
(D-001206) consisted of four off-target siRNA duplexes. HEK-CLR-RAMP1 
cells (0.5 × 10
6 cells per well of 6-well plate in antibiotic-free medium) 
were transfected with 200 pmol siRNA and 5 μl of DharmaFECT 1 accord-
ing to the manufacturer’s instructions. Cells were incubated in the transfec-
tion medium for 72 h, and then used for experiments.
Flow cytometry
HEK-CLR-RAMP1 cells expressing ECE-1c-HSV were incubated with goat 
anti-HSV (1 mg/ml, 1 h, 4°C). Cells were washed, stimulated with CGRP 
(100 nM, 30 min, 37°C), and incubated with donkey anti–goat-FITC 
(1:200, 1 h, 4°C). Cells were analyzed using a FACSort (Becton Dickinson) 
and CELLQuest 3.3 software (BD Biosciences). Background ﬂ  uorescence 
was measured in cells treated with secondary antibody only and was sub-
tracted from the ﬂ  uorescence histograms of the treatment groups.
Statistics
Results are expressed as mean ± SE from n ≥ 3 experiments. Results are 
compared by t test for two comparisons or ANOVA and Student-Newman-
Kuel’s test for multiple comparisons, with P < 0.05 considered signiﬁ  cant. 
Representative images of cells and gels are shown from n ≥ 3 experiments.
Online supplemental material
Fig. S1 shows endogenous expression of ECE-1a-d, B2R, CLR, RAMP1, 
and AT1AR in HEK, SK-N-MC, and A549 cell lines. Fig. S2 shows that 
CGRP induces trafﬁ  cking of CLR to endosomes containing ECE-1. The 
chromatograms in Fig. S3 show that rhECE-1 degrades CGRP, and that 
endogenous ECE-1 degrades endocytosed 
125I-His
8-CGRP in HEK cells. 
Fig. S4 shows that ECE-1 siRNA effectively suppresses levels of ECE-1 in 
HEK cells. Fig. S5 shows that SM-19712 does not affect CGRP-induced 
[Ca
2+]i signaling or desensitization of [Ca
2+]I signaling in HEK-CLR-RAMP1 
and SK-N-MC cells. The ﬁ  gure also shows that SM-19712 and baﬁ  lo-
mycin A1 do not affect BK-induced [Ca
2+]i signaling or desensitization in 
HEK cells. Online supplemental material is available at http://www.jcb.
org/cgi/content/full/jcb.200704053/DC1.
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